Abstracts tagged "Scleroderma"

Abstract Number: 130 • 2018 ACR/ARHP Annual Meeting
The Role of Cofilin, an Actin Associated Protein, in Activation of Systemic Sclerosis Vascular Smooth Muscle Cells
Shadia Nada, Bashar Kahaleh and Nezam Altorok, Medicine/Rheumatology, University of Toledo, Toledo, OH
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterized by activation of the immune system, vascular dysfunction and tissue fibrosis. Vascular dysfunction in…
Abstract Number: 811 • 2018 ACR/ARHP Annual Meeting
Identification of Risk Factors for Gastric Antral Vascular Ectasia (GAVE) Among Systemic Sclerosis Patients
Naomi Serling-Boyd¹, Shufeng Li², David Fiorentino², Laren Becker³, Nielsen Fernandez-Becker³, John Clarke⁴ and Lorinda Chung^5,6, ¹Medicine, Stanford University School of Medicine, Stanford, CA, ²Dermatology, Stanford University School of Medicine, Stanford, CA, ³Gastroenterology, Stanford University School of Medicine, Palo Alto, CA, ⁴Gastroenterology, Stanford University School of Medicine, Stanford, CA, ⁵VA Palo Alto Health Care System, Palo Alto, CA, ⁶Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Gastric Antral Vascular Ectasia (GAVE) is a vascular manifestation of systemic sclerosis (SSc) characterized by erythematous streaks and longitudinal rugal folds in the stomach…
Abstract Number: 902 • 2018 ACR/ARHP Annual Meeting
Longitudinal Trends in Clinical Disease Features after Myeloablative Autologous Stem-Cell Transplantation or Cyclophosphamide in Severe Scleroderma
Lynette Keyes-Elstein¹, Ellen Goldmuntz², Ashley Pinckney³, Leslie Crofford⁴, Daniel E. Furst⁵, Maureen D. Mayes⁶, Peter McSweeney⁷, Richard Nash⁷, Beverly Welch⁸ and Keith Sullivan⁹, ¹Biostatistics, Rho Federal Systems, Inc, Chapel Hill, NC, ²NIAID, NIH, Bethesda, MD, ³Rho Federal Systems, Inc., Chapel Hill, NC, ⁴Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁵UCLA, Los Angeles, CA, ⁶Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁷Colorado Blood Cancer Institute, Denver, CO, ⁸6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ⁹Duke University Medical Center, Durham, NC
Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) study established the long-term superiority of hematopoietic stem cell transplant (HSCT) over cyclophosphamide (CYC) [Sullivan KM, et al.…
Abstract Number: 919 • 2018 ACR/ARHP Annual Meeting
A Machine Learning Classifier for Assigning Individual Patients with Systemic Sclerosis to Intrinsic Molecular Subsets
Jennifer Franks¹, Viktor Martyanov¹, Guoshuai Cai², Yue Wang³, Tammara A. Wood¹ and Michael L. Whitfield⁴, ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Environmental Health Sciences, Arnold School of Public Health at University of South Carolina, Columbia, SC, ³Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: High-throughput gene expression profiling of skin biopsies from patients with systemic sclerosis (SSc) has identified four “intrinsic” gene expression subsets conserved across multiple cohorts…
Abstract Number: 1741 • 2018 ACR/ARHP Annual Meeting
Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis
Svetlana I. Nihtyanova¹, Alper Sari², Voon H. Ong³ and Christopher P. Denton⁴, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Division of Medicine, University College London, London, United Kingdom, ⁴University College London, London, United Kingdom
Background/Purpose: Although severity of skin involvement and change in skin thickness over time vary substantially between patients with diffuse cutaneous systemic sclerosis (dcSSc), for the…
Abstract Number: 1820 • 2018 ACR/ARHP Annual Meeting
Myeloablative Autologous Hematopoietic Stem Cell Transplantation for Severe Scleroderma: Long-Term Outcomes 6-11 Years after Entry on a Randomized Study Comparing Transplantation and Cyclophosphamide
Keith Sullivan¹, Ashley Pinckney², Ellen Goldmuntz³, Beverly Welch⁴, Dinesh Khanna⁵, Robert W. Simms⁶, Suzanne Kafaja⁷, George Georges⁸, Jan Storek⁹, Mary Ellen Csuka¹⁰, Richard Nash¹¹, Daniel E. Furst¹², Leslie Crofford¹³, Peter McSweeney¹¹, Maureen D. Mayes¹⁴ and Lynette Keyes-Elstein¹⁵, ¹Duke University Medical Center, Durham, NC, ²Rho Federal Systems, Inc., Chapel Hill, NC, ³NIAID, NIH, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁸Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Medicine, Medical College of Wisconsin, Milwaukee, WI, ¹¹Colorado Blood Cancer Institute, Denver, CO, ¹²University of Washington, Seattle, WA, ¹³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹⁴Rheumatology, University of Texas McGovern Medical School, Houston, TX, ¹⁵Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC
Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated that for adults with severe scleroderma (ACR 1995 criteria) and internal organ involvement, myeloablative CD34+selected autologous…
Abstract Number: 2701 • 2018 ACR/ARHP Annual Meeting
Botulinum Toxin in the Management of Raynaud’s Phenomenon
Daniel Ennis^1,2, Zareen Ahmad³, Keshini Devakandan¹, Melanie A Anderson⁴ and Sindhu Johnson¹, ¹Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴University Health Network Library Services, Toronto General Hospital, Toronto, ON, Canada
Background/Purpose: The objectives of this study were to evaluate the effectiveness and safety of botulinum toxin injection in Raynaud’s phenomenon. Methods: Medline and Embase databases…
Abstract Number: 2708 • 2018 ACR/ARHP Annual Meeting
Current Management of Early Diffuse Cutaneous Systemic Sclerosis in US Scleroderma Centers
Rebecca B. Blank¹, Jessica K. Gordon², Jackie Szymonifka³, Shervin Assassi⁴, Elana J. Bernstein⁵, Flavia V. Castelino⁶, Robyn T. Domsic⁷, Faye N. Hant⁸, Monique Hinchcliff⁹, Kate Homer¹⁰, Ami A. Shah¹¹, Victoria Shanmugam¹², Virginia D. Steen¹³, Tracy M. Frech¹⁴ and Dinesh Khanna¹⁵, ¹Internal Medicine, New York Presbyterian-Weill Cornell Hospital, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴University of Texas McGovern Medical School, Houston, TX, ⁵Rheumatology, Columbia University, New York, NY, ⁶Rheumatology, Harvard Medical School, Boston, MA, ⁷Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology, Medical University of South Carolina, Charleston, SC, ⁹Division of Rheumatology, Northwestern University Medical School, Chicago, IL, ¹⁰Department of Internal Medicine, Rheumatology Division, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹²Rheumatology, The George Washington University, Washington, DC, ¹³Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ¹⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Standard treatment for the diverse aspects of diffuse cutaneous systemic sclerosis (dcSSc) is not yet well defined although experts have described therapeutic algorithms. The…
Abstract Number: 750 • 2017 ACR/ARHP Annual Meeting
Diltiazem Gel As a New Local Treatment for Scleroderma Digital Ulcers
Mohammad Ali Nazarinia¹, Elmira Esmaeilzadeh² and Saeedeh Shenavandeh², ¹Shiraz Geriatric Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, Shiraz, Iran (Islamic Republic of), ²Department of Internal Medicine, Division of Rheumatology, Shiraz University of Medical Sciences, Shiraz, Iran., Shiraz, Iran (Islamic Republic of)
Background/Purpose: Assessing the effect of Diltiazem gel on healing process of scleroderma digital ulcers and comparing its effect with Nitroglycerin ointment and placebo. Methods: Ninety…
Abstract Number: 1680 • 2017 ACR/ARHP Annual Meeting
Higher Baseline Monocyte Count Is Associated with More Extensive Skin Involvement and Higher Mortality in Systemic Sclerosis
Vishnu Mohan¹, Purvesh Khatri², Samuel Theodore¹, Julio Charles¹, Hau Pham¹, Deepthi Nair¹, Madeleine Scott², John D. Reveille¹, Maureen D. Mayes¹ and Shervin Assassi¹, ¹University of Texas McGovern Medical School, Houston, TX, ²Stanford University, Stanford, CA
Background/Purpose: Macrophages are the primary inflammatory cell type present in the systemic sclerosis (SSc) skin. Circulating monocytes can give rise to profibrotic inflammatory cells such…
Abstract Number: 2666 • 2017 ACR/ARHP Annual Meeting
The Clinical Utility of Flow-Mediated Dilation in Systemic Sclerosis Digital Ulcer Assessment
Tracy M. Frech¹, Daniel Machin², Maureen Murtaugh³ and Anthony Donato², ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ³University of Utah, Salt Lake, UT
Background/Purpose: Systemic sclerosis (SSc, scleroderma) patients can have the end-stage vasculopathy manifestation of a digital ulcer (DU). Brachial artery flow mediated dilation (FMD) is an…
Abstract Number: 2681 • 2017 ACR/ARHP Annual Meeting
Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome
Samar Alharbi¹, Zareen Ahmad², Zahi Touma³, Arthur Bookman⁴, Jorge Sánchez-Guerrero⁵ and Sindhu Johnson⁶, ¹Division of Rheumatology, University of Toronto, Toronto Scleroderma Program, Sinai Health System, University Health Network,, Toronto, ON, Canada, ²Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ⁴Division of Rheumatology, University Health Network, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, ⁶Division of Rheumatology, University of Toronto, Toronto Scleroderma Program, Sinai Health Systems and University Health Network, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is an immune disorder characterized by vasculopathy and fibrosis. SSc may overlap with another disease such as systemic lupus erythematosus (SLE).…
Abstract Number: 2896 • 2016 ACR/ARHP Annual Meeting
Safety and Effectiveness of Hyperbaric Oxygen Therapy for Systemic Sclerosis Ulcers
Susan Armstrong¹, A. Wayne Evans², Zareen Ahmad³ and Sindhu R. Johnson⁴, ¹Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Hyperbaric Medicine Unit, Department of Anaesthesia, Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Vascular complications of systemic sclerosis (SSc, scleroderma) can result in ulcers in the distal extremities, which limit function and are often refractory to conventional…
Abstract Number: 3247 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Belimumab with Background Mycophenolate for Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Placebo Controlled, Pilot Trial
Jessica K. Gordon¹, Eliza Pelrine², Yuo-Yu Lee³, Cynthia Magro⁴, Elana J. Bernstein⁵, Horatio F. Wildman⁶ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Pathology, Weill Cornell Medical College, New York, NY, ⁵Department of Medicine, Division of Rheumatology, Columbia University, New York, NY, ⁶Dermatology, Weill Cornell Medical College, New York, NY
Background/Purpose: Abnormalities of B cell function are part of the pathogenesis of systemic sclerosis (SSc), and B-lymphocyte stimulator (BLyS) is increased in the serum and…
Abstract Number: 3248 • 2016 ACR/ARHP Annual Meeting
Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post-Hoc Analyses from the Scleroderma Lung Study I and II
Rajaie Namas^1,2, Donald P. Tashkin³, Holly Wilhalme⁴, Daniel E. Furst⁵, Chi-hong Tseng⁶, Michael Roth⁶, Suzanne Kafaja⁷, Elizabeth R. Volkmann⁴, Philip J. Clements⁶ and Dinesh Khanna⁸, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ³David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵UCLA, Los Angeles, CA, ⁶Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸University of Michigan, Ann Arbor, MI
Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II. Background/Purpose: Assess the efficacy of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].